DeepMed Research

Ocular Therapeutix, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 2006-01-01

Employees: 267

Market Cap: -

Website: http://www.ocutx.com

Clinical Trials

Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration

Phase 3

Recruiting

Conditions: Neovascular Age-related Macular Degeneration

Interventions: Drug: OTX-TKI
Drug: Aflibercept

First Posted Date: 2024-07-11

Last Posted Date: 2025-05-06

Lead Sponsor: Ocular Therapeutix, Inc.

Target Recruit Count: 825

Registration Number: NCT06495918

Locations: 🇺🇸
Associated Retina Consultant, Gilbert, Arizona, United States
🇺🇸
Associated Retina Consultants, Ltd., Phoenix, Arizona, United States
🇺🇸
Retinal Research Institute, LLC, Phoenix, Arizona, United States

and more 83 locations

Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration

Phase 3

Active, not recruiting

Conditions: Neovascular Age-Related Macular Degeneration

Interventions: Drug: OTX-TKI (axitinib implant)
Drug: Aflibercept

First Posted Date: 2024-01-25

Last Posted Date: 2025-04-18

Lead Sponsor: Ocular Therapeutix, Inc.

Target Recruit Count: 344

Registration Number: NCT06223958

Locations: 🇺🇸
Retina Associates of Cleveland, Inc. - Beachwood, Beachwood, Ohio, United States
🇺🇸
Associated Retina Consultants - Phoenix, Phoenix, Arizona, United States
🇺🇸
CA CRC California Retina Consultants, Oxnard, California, United States

and more 102 locations

OTX-DED for the Short-term Treatment of the Symptoms of Dry Eye Disease (DED)

Phase 2

Completed

Conditions: Eye Diseases
Dry Eye Syndromes

Interventions: Drug: Controlled Insertion
Drug: OTX-DED
Drug: Collagen Punctal Plug

First Posted Date: 2023-04-18

Last Posted Date: 2024-07-10

Lead Sponsor: Ocular Therapeutix, Inc.

Target Recruit Count: 100

Registration Number: NCT05814757

Locations: 🇺🇸
Ocular Therapeutix, Memphis, Tennessee, United States

Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI in Subjects With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy

Phase 1

Active, not recruiting

Conditions: Non-proliferative Diabetic Retinopathy

Interventions: Drug: OTX-TKI
Drug: Sham

First Posted Date: 2023-01-25

Last Posted Date: 2023-12-08

Lead Sponsor: Ocular Therapeutix, Inc.

Target Recruit Count: 21

Registration Number: NCT05695417

Locations: 🇺🇸
Ocular Therapeutix Inc, Bellaire, Texas, United States
🇺🇸
Ocular Therapeutiux, Inc., Austin, Texas, United States
🇺🇸
Ocular Therapeutix, Inc, San Antonio, Texas, United States

and more 2 locations

A Study to Evaluate the Efficacy and Safety of OTX-TIC (Travoprost) Intracameral Implant for Patients With Open-angle Glaucoma (OAG) or Ocular Hypertension (OHT)

Phase 2

Completed

Conditions: Ocular Hypertension
Open Angle Glaucoma

Interventions: Drug: OTX-TIC low dose Travoprost Intracameral Implant
Drug: OTX-TIC high dose Travoprost Intracameral Implant
Drug: Durysta, Bimatoprost Intracameral Implant 10 µg

First Posted Date: 2022-04-19

Last Posted Date: 2025-03-21

Lead Sponsor: Ocular Therapeutix, Inc.

Target Recruit Count: 83

Registration Number: NCT05335122

Locations: 🇺🇸
Ocular Therapeutiux, Inc., Fargo, North Dakota, United States
🇺🇸
Ocular Therapeutix, Inc., Kenosha, Wisconsin, United States
🇺🇸
Ocular Therapeutix Inc, Oklahoma City, Oklahoma, United States

and more 1 locations

An Observational, Qualitative Study Assessing Eye Drop Administration

Recruiting

Conditions: Ocular Injury

Interventions: Drug: Artificial Tears

First Posted Date: 2022-04-01

Last Posted Date: 2022-09-16

Lead Sponsor: Ocular Therapeutix, Inc.

Target Recruit Count: 300

Registration Number: NCT05307081

Locations: 🇺🇸
Vance Thompson Vision, Sioux Falls, South Dakota, United States

Study Evaluating the Treatment of OTX-TKI for Subjects With Neovascular Age-related Macular Degeneration

Phase 1

Completed

Conditions: Neovascular Age-Related Macular Degeneration

Interventions: Drug: OTX-TKI/Sham
Drug: Aflibercept/Sham

First Posted Date: 2021-08-04

Last Posted Date: 2024-01-26

Lead Sponsor: Ocular Therapeutix, Inc.

Target Recruit Count: 21

Registration Number: NCT04989699

Locations: 🇺🇸
Ocular Therapeutix, The Woodlands, Texas, United States

A Human Factors Study to Evaluate a Novel Intracanalicular Insertion Device in Healthy Subjects

Early Phase 1

Terminated

Conditions: Healthy

Interventions: Drug: Dexamethasone Ophthalmic
Device: Dilator

First Posted Date: 2021-06-30

Last Posted Date: 2023-02-06

Lead Sponsor: Ocular Therapeutix, Inc.

Target Recruit Count: 2

Registration Number: NCT04945824

Locations: 🇺🇸
Ocular Therapeutix, Inc., Sioux Falls, South Dakota, United States

To Assess the Efficacy and Safety of OTX-DED for the Short-term Treatment of Signs and Symptoms of Dry Eye Disease

Phase 2

Completed

Conditions: Dry Eye

Interventions: Drug: OTX-DED

First Posted Date: 2021-02-10

Last Posted Date: 2023-02-22

Lead Sponsor: Ocular Therapeutix, Inc.

Target Recruit Count: 172

Registration Number: NCT04747977

Locations: 🇺🇸
Ocular Therapeutix, Inc, Mission Hills, California, United States
🇺🇸
Ocular Therapeutix, Poughkeepsie, New York, United States
🇺🇸
Ocular Therapeutix, Inc., League City, Texas, United States

A Study Assessing the Safety and Efficacy of Dextenza® for the Treatment of Ocular Pain and Inflammation Following Surgery for Pediatric Cataract

Phase 3

Completed

Conditions: Cataract

Interventions: Drug: Prednisolone acetate ophthalmic suspension USP 1%
Drug: Dextenza Ophthalmic Insert

First Posted Date: 2020-09-07

Last Posted Date: 2024-04-15

Lead Sponsor: Ocular Therapeutix, Inc.

Target Recruit Count: 65

Registration Number: NCT04539548

Locations: 🇺🇸
Ocular Therapeutix, Madison, Wisconsin, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy